Detection and clinical application of minimal residual disease in multiple myeloma

doi:10.3760/cma.j.issn.1673-422X.2018.01.013

Abstract

Abstract: Minimal residual disease (MRD) is a very important prognostic factor in multiple myeloma (MM). The major types of MRD tests include cellbased test (multiparameter flow cytometry) and molecular tests (including PCR and gene sequencing), and the various techniques have inherent advantages and limitations. In clinical application, MRD negative can significantly prolong progressionfree survival and overall survival of patients who receive hematopoietic stem cell transplantation and conventional chemotherapy. Moreover, the MRD status is of great significance to the selection of treatment options.

Key words: Multiple myeloma, Neoplasm, residual

Liu Xiaolan, Guan Tao, Su Liping. Detection and clinical application of minimal residual disease in multiple myeloma[J]. Journal of International Oncology, 2018, 45(1): 56-.

References

［1］ Munshi NC, AvetLoiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a metaanalysis［J］. JAMA Oncol, 2017, 3(1): 2835. DOI: 10.1001/jamaoncol.2016.3160. ［2］Landgren O, Gormley N, Turley D, et al. Flow cytometry detection of minimal residual disease in multiple myeloma: lessons learned at FDANCI roundtable symposium［J］. Am J Hematol, 2014, 89(12): 11591160. DOI: 10.1002/ajh.23831. ［3］ Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders［J］. Haematologica, 2008, 93(3): 431438. DOI: 10.3324/haematol.11080. ［4］ Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma Ⅸ Study［J］. J Clin Oncol, 2013, 31(20): 25402547. DOI: 10.1200/JCO.2012.46.2119. ［5］ Ladetto, M, Brüggemann M, Monitillo L, et al. Nextgeneration sequencing and realtime quantitative PCR for minimal residual disease detection in Bcell disorders［J］. Leukemia, 2014, 28(6): 12991307. DOI: 10.1038/leu.2013.375. ［6］ Bai Y, Wong KY, Fung TK, et al. High applicability of ASORQPCR for detection of minimal residual disease in multiple myeloma by entirely patientspecific primers/probes［J］. J Hematol Oncol, 2016, 9(1): 107. ［7］ MartinezLopez J, FernándezRedondo E, GarcíaSánz R, et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescentPCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study［J］. Br J Haematol, 2013, 163(5): 581589. DOI: 10.1111/bjh.12576. ［8］Faham M, Zheng J, Moorhead M, et al. Deepsequencing approach for minimal residual disease detection in acute lymphoblastic leukemia［J］. Blood, 2012, 120(26): 51735180. DOI: 10.1182/blood201207444042. ［9］ MartinezLopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma［J］. Blood, 2014, 123(20): 30733079. DOI: 10.1182/blood201401550020. ［10］ Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQPCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry［J］. Leukemia, 2014, 28(2): 391397. DOI: 10.1038/leu.2013.217. ［11］ Silvennoinen R, Lundan T, Kairisto V, et al. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQPCR in multiple myeloma［J］. Blood Cancer J, 2014, 4: e250. DOI: 10.1038/bcj.2014.69. ［12］ Paiva B, Vidriales MB, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation［J］. Blood, 2008, 112(10): 40174023. DOI: 10.1182/blood200805159624. ［13］ de Tute RM, Rawstron AC, Gregory WM, et al. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen［J］. Haematologica, 2016, 101(2): e69e71. DOI: 10.3324/haematol.2015.128215. ［14］ Ladetto M, Ferrero S, Drandi D, et al. Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma［J］. Leukemia, 2016, 30(5): 12111214. DOI: 10.1038/leu.2015.269. ［15］ de Larrea CF, Cibeira MT, Elena M, et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition［J］. Blood, 2009, 114(24): 49544956. DOI: 10.1182/blood200906224832. ［16］ Mateos MV, Oriol A, MartinezLópez J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?［J］. Blood, 2014, 124(12): 18871893. ［17］ Ferrero S, Ladetto M, Drandi D, et al. Longterm results of the GIMEMA VEL03096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics′ impact on survival［J］. Leukemia, 2015, 29(3): 689695. DOI: 10.1038/leu.2014.219.

[1]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan. Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells [J]. Journal of International Oncology, 2024, 51(3): 129-136.
[2]	Zhang Yuxiao, Zhang Liansheng, Li Lijuan. Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma [J]. Journal of International Oncology, 2023, 50(2): 122-125.
[3]	Zhao Jianhao, Duan Yanchao. Research progress in the pathogenesis of extramedullary disease in multiple myeloma [J]. Journal of International Oncology, 2023, 50(1): 55-59.
[4]	Gao Shan, Lu Minqiu, Shi Lei, Chu Bin, Fang Lijuan, Xiang Qiuqing, Wang Yutong, Ding Yuehua, Bao Li. Clinical efficacy and safety of ixazomib-based therapy in the treatment of relapsed or refractory multiple myeloma [J]. Journal of International Oncology, 2022, 49(5): 286-291.
[5]	Sun Ruijie, Shan Ningning. Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma [J]. Journal of International Oncology, 2021, 48(6): 381-384.
[6]	Hou Yuanmei, Li Junpeng. Recent advances in immunotherapy for relapsed or refractory multiple myeloma [J]. Journal of International Oncology, 2020, 47(12): 765-768.
[7]	Yao Yixuan, Wang Huan, Xia Jun, Wang Jing, Sun Chao, Sun Hongli, Zhou Xin. Correlations between peripheral absolute lymphocyte count and clinicopathological characteristics of the elderly patients with multiple myeloma and its prognosis [J]. Journal of International Oncology, 2018, 45(6): 347-351.
[8]	Yuan Qing, Chen Shaoshui. Application of circulating microRNAs in multiple myeloma [J]. Journal of International Oncology, 2018, 45(1): 53-.
[9]	WANG Wei-Yuan, GUO Dong-Mei, HAN Tian-Jie, TENG Qing-Liang. Role and treatment strategy of hypoxia in the pathogenesis of multiple myeloma [J]. Journal of International Oncology, 2016, 43(7): 552-554.
[10]	LI Chun-Pu, WANG Jing, LIU Yan, WANG Ling, LI Ban-Ban, ZHANG Kai-Gang, GUO Dong-Mei. Inhibition of RPMI8226 myeloma cell xenografted tumor angiogenesis by downregulation of Notch1 [J]. Journal of International Oncology, 2015, 42(8): 661-.
[11]	Wang Yingying, Zhu Qi. cAMP signaling pathway and multiple myeloma [J]. Journal of International Oncology, 2014, 41(5): 368-370.
[12]	LI Ban-Ban, GUO Dong-Mei, TENG Qing-Liang. Roles of hypoxia and Notch1 in multiple myeloma [J]. Journal of International Oncology, 2013, 40(7): 542-546.
[13]	WU Zhi-Xing, 吕Kuan , ZHANG Ke, KONG Xiang-Hui, GUO Hui-Min. Comparative study of 18FFDG PET/CT and 99TcmMDP bone scintigraphy in detecting multiple myeloma bone destruction [J]. Journal of International Oncology, 2013, 40(12): 940-944.
[14]	WANG Ming-Ming, HU Jun-Pei, ZOU Li-Fang, DOU Hong-Ju, YAO Yi-Yun, ZHU Qi. Effects of arsenic trioxide on intracelluar SOCS-1 gene methylation and P-STAT3 expression in multiple myeloma cells [J]. Journal of International Oncology, 2012, 39(8): 633-636.
[15]	LIU Qin-Qin, GUO Dong-Mei, TENG Qing-Liang. Notch signal pathway and the pathogenesis of multiple myeloma [J]. Journal of International Oncology, 2012, 39(7): 544-546.